<DOC>
	<DOCNO>NCT01525017</DOCNO>
	<brief_summary>The primary objective study answer question `` Is possible inject Combig-DC vaccine renal tumour without get unacceptable side effect '' ? Patients newly diagnose metastatic renal cell carcinoma get Combig-DC vaccination two occasion two week period ( day 1 day 14 ) . After another two week kidney eliminate . Adverse event register , well change vital sign ( heart rate , blood pressure body temperature ) lab parameter . Immunologic response evaluate measure immunologic marker blood tumour tissue , measure size metastasis three month nephrectomy .</brief_summary>
	<brief_title>A Clinical Study Evaluate Safety Immunologic Response COMBIG-DC , Patients With Metastatic Kidney Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Be inform nature study provide write informed consent 2 . At least 18 year age . 3 . Diagnosis renal cell carcinoma least one distant metastasis , and/or one distant lymph node metastasis . 4 . Tumor size ( renal cell carcinoma ; primary tumor ) least 4.0 cm long diameter measure CT . Distant metastasis least 1 cm diameter measure CT distant lymph node metastasis least 2,5 cm diameter measure CT. Clinical stage 'T1b ; NX ; M1 ' 5 . Adequate hematological parameter , i.e : BLeukocyte count ≥ 4.5 x 109/L BPlatelet count ≥ 150 x109/L BHaemoglobin ≥ 100 g/L 6 . Women Childbearing Potential ( WOCBP ) use adequate contraception ( oral injectable contraceptive , hormone release intrauterine device ) throughout study period . 1 . Performance status &gt; ECOG 2 optimization analgesic 2 . Adequate coagulation parameter , i.e : PProthrombin complex ( PK ) , PAPT time 3 . Ongoing treatment systemic corticosteroid ( inhale , intranasal local steroid accept ) within 28 day first vaccination . 4 . Previously know ongoing active autoimmune disease require treatment systemic immunosuppressive agent . E.g . inflammatory bowel disease , multiple sclerosis , sarcoidosis , psoriasis , autoimmune hemolytic anemia , rheumatoid arthritis , SLE , vasculitis , Sjögren 's syndrome , scleroderma , autoimmune hepatitis , rheumatological disease . 5 . Patients previous ongoing skin malignancy ( basalcell carcinoma , squamous cell carcinoma , melanoma ) , hematological solid malignancy blood dysfunction . 6 . Ongoing infection require treatment antibiotic . 7 . Known major reaction/adverse event connection previously make vaccination ( e.g . asthma , anaphylaxis serious reaction ) 8 . Known malignancy CNS . 9 . Active latent virus disease ( HIV , HBV HCV ) . 10 . Ongoing pregnancy lactation . Females need negative pregnancy test screen visit . 11 . Life expectancy le 3 month . 12 . Concomitant exposure investigational product . 13 . Any reason , opinion investigator , contraindicate patient participates study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>